Jayde Whittingham-Dowd

Jayde Whittingham-Dowd

Auto-generated profile, based on publicly available information

Jayde Whittingham-Dowd

Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LCLaura Campbell
Laura Campbell
MHMatthew R. Hepworth
Matthew R. Hepworth
JWJayde Whittingham-Dowd
Jayde Whittingham-Dowd
STSeona Thompson
Seona Thompson
ABAllison J. Bancroft
Allison J. Bancroft
RGRichard Grencis
Richard Grencis
Host immunity to parasitic nematodes requires the generation of a robust type 2 cytokine response, characterized by the production of interleukin 13 (IL-13), which drives expulsion. Here, we show that infection with helminths in the intestine also induces an ILC2-driven, IL-13–dependent goblet cell hyperplasia and increased production of mucins (Muc5b and Muc5ac) at distal sites, including the lungs and other mucosal barrier sites. Critically, we show that type 2 priming of lung tissue through increased mucin production inhibits the progression of a subsequent lung migratory helminth infection and limits its transit through the airways. These data show that infection by gastrointestinal-dwelling helminths induces a systemic innate mucin response that primes peripheral barrier sites for protection against subsequent secondary helminth infections. These data suggest that innate-driven priming of mucus barriers may have evolved to protect from subsequent infections with multiple helminth species, which occur naturally in endemic areas.

1 November 2012 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
PMPeter Magee
Peter Magee
SPStephen Pearson
Stephen Pearson
JWJayde Whittingham-Dowd
Jayde Whittingham-Dowd
JAJeremy Allen
Jeremy Allen

1 September 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Mohammed RohaimMohammed Rohaim
Mohammed Rohaim
Emily ClaytonEmily Clayton
Emily Clayton
ISIrem Sahin
Irem Sahin
Julianne VilelaJulianne Vilela
Julianne Vilela
MKManar Khalifa
Manar Khalifa
MMMuhammad Munir
Muhammad Munir
Until vaccines and effective therapeutics become available, the practical solution to transit safely out of the current coronavirus disease 19 (CoVID-19) lockdown may include the implementation of an effective testing, tracing and tracking system. However, this requires a reliable and clinically validated diagnostic platform for the sensitive and specific identification of SARS-CoV-2. Here, we report on the development of a de novo, high-resolution and comparative genomics guided reverse-transcribed loop-mediated isothermal amplification (LAMP) assay. To further enhance the assay performance and to remove any subjectivity associated with operator interpretation of results, we engineered a novel hand-held smart diagnostic device. The robust diagnostic device was further furnished with automated image acquisition and processing algorithms and the collated data was processed through artificial intelligence (AI) pipelines to further reduce the assay run time and the subjectivity of the colorimetric LAMP detection. This advanced AI algorithm-implemented LAMP (ai-LAMP) assay, targeting the RNA-dependent RNA polymerase gene, showed high analytical sensitivity and specificity for SARS-CoV-2. A total of ~200 coronavirus disease (CoVID-19)-suspected NHS patient samples were tested using the platform and it was shown to be reliable, highly specific and significantly more sensitive than the current gold standard qRT-PCR. Therefore, this system could provide an efficient and cost-effective platform to detect SARS-CoV-2 in resource-limited laboratories.

1 February 2008 in Placenta
Verified
Journal Article
Closed access
CJCarolyn Jones
Carolyn Jones
LHLynda K Harris
Lynda K Harris
JWJ. Whittingham
J. Whittingham
JAJohn Aplin
John Aplin
TMT.M. Mayhew
T.M. Mayhew

8 December 2019 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
RHRebecca B Hughes
Rebecca B Hughes
JWJayde Whittingham-Dowd
Jayde Whittingham-Dowd
RSRachel E Simmons
Rachel E Simmons
SCSteven J Clapcote
Steven J Clapcote
SBSusan J Broughton
Susan J Broughton
NDNeil Dawson
Neil Dawson
2p16.3 deletions, involving heterozygous NEUREXIN1 (NRXN1) deletion, dramatically increase the risk of developing neurodevelopmental disorders, including autism and schizophrenia. We have little understanding of how NRXN1 heterozygosity increases the risk of developing these disorders, particularly in terms of the impact on brain and neurotransmitter system function and brain network connectivity. Thus, here we characterize cerebral metabolism and functional brain network connectivity in Nrxn1α heterozygous mice (Nrxn1α+/− mice), and assess the impact of ketamine and dextro-amphetamine on cerebral metabolism in these animals. We show that heterozygous Nrxn1α deletion alters cerebral metabolism in neural systems implicated in autism and schizophrenia including the thalamus, mesolimbic system, and select cortical regions. Nrxn1α heterozygosity also reduces the efficiency of functional brain networks, through lost thalamic “rich club” and prefrontal cortex (PFC) hub connectivity and through reduced thalamic-PFC and thalamic “rich club” regional interconnectivity. Subanesthetic ketamine administration normalizes the thalamic hypermetabolism and partially normalizes thalamic disconnectivity present in Nrxn1α+/− mice, while cerebral metabolic responses to dextro-amphetamine are unaltered. The data provide new insight into the systems-level impact of heterozygous Nrxn1α deletion and how this increases the risk of developing neurodevelopmental disorders. The data also suggest that the thalamic dysfunction induced by heterozygous Nrxn1α deletion may be NMDA receptor-dependent.

27 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CJCatherine E Jobbings
Catherine E Jobbings
HSHilary Sandig
Hilary Sandig
JWJayde K Whittingham-Dowd
Jayde K Whittingham-Dowd
IRIan S Roberts
Ian S Roberts
SBSilvia Bulfone-Paus
Silvia Bulfone-Paus
Whilst mast cells participate in the immune defence against the intracellular bacterium Listeria monocytogenes, there is conflicting evidence regarding the ability of L. monocytogenes to infect mast cells. It is known that the pore-forming toxin listeriolysin (LLO) is important for mast cell activation, degranulation and the release of pro-inflammatory cytokines. Mast cells, however, are a potential source of a wide range of cytokines, chemokines and other mediators including osteopontin, which contributes to the clearing of L. monocytogenes infections in vivo, although its source is unknown. We therefore aimed to resolve the controversy of mast cell infection by L. monocytogenes and investigated the extent of mediator release in response to the bacterium. In this paper we show that the infection of bone marrow-derived mast cells by L. monocytogenes is inefficient and LLO-independent. LLO, however, is required for calcium-independent mast cell degranulation as well as for the transient and selective downregulation of cell surface CD117 (c-kit) on mast cells. We demonstrate that in addition to the key pro-inflammatory cytokines TNF-α and IL-6, mast cells release a wide range of other mediators in response to L. monocytogenes. Osteopontin, IL-2, IL-4, IL-13 and granulocyte macrophage colony-stimulating factor (GM-CSF), and chemokines including CCL2, CCL3, CCL4 and CCL5 are released in a MyD88-dependent manner. The wide range of mediators released by mast cells in response to L. monocytogenes may play an important role in the recruitment and activation of a variety of immune cells in vivo. The cocktail of mediators, however, is unlikely to skew the immune response to a particular effector response. We propose that mast cells provide a hitherto unreported source of osteopontin, and may provide an important role in co-ordinating the immune response during Listeria infection.